Dementia drug from Alector fails to gradual affected person decline in trial
An experimental drug from Alector Inc. didn’t gradual the decline of sufferers with frontotemporal dementia in a late-stage examine, the corporate introduced Tuesday.
Alector mentioned it might lay off 49% of its staff in consequence. The corporate employed 238 individuals as of final December.
The drug, referred to as latozinemab, was certainly one of a number of experimental medication that had entered medical trials for frontotemporal dementia, or FTD, a type of dementia thought to have an effect on round 50,000 to 60,000 People.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
